CliffBio
small molecule

QUVIVIQ

DARIDOREXANT HYDROCHLORIDE

Loss of exclusivityDecember 2034latest FDA-listed patent expiry
CompanyIdorsia →See this company's full patent-cliff portfolio

Drug detail

Brand nameQUVIVIQ
Active ingredientDARIDOREXANT HYDROCHLORIDE
StrengthEQ 25MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalApril 2022
Marketing statusRX

Listed patents

PatentExpiresType
10023560December 2034use U-620
9790208December 2034substance, product
9732075June 2033substance, product

Regulatory exclusivity

CodeExpires
M-200September 2027
M-310September 2027
NCEApril 2027

More from Idorsia

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

QUVIVIQ patent cliff — loss of exclusivity December 2034 | CliffBio